These data are supported by a recent study investigating BRaf and MEK inhibitors in hepatocellular carcinoma where the authors observed that administration of a low concentration of sorafenib leads to sustained, and in some cases increased, MAPK signaling via B- and CRaf dimerization [43]. This evidence concerns the gene BRAF and hepatocellular carcinoma.